Evaluating oxygen levels in COVID-19 patients
Prognostic Value of Transcutaneous Partial Pressure of Oxygen in Patients With Novel Coronavirus Infection
This study is testing if measuring oxygen levels in COVID-19 patients can help predict how they will respond to treatment and their chances of recovery, especially for older adults with serious health issues.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Southeast University, China Academic / other |
| Locations | 1 site (Nanjing, Jiangsu) |
| Trial ID | NCT05682612 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the prognostic value of transcutaneous oxygen pressure (PtcO2) in patients with COVID-19 who are at risk of developing acute respiratory distress syndrome (ARDS). It focuses on individuals aged 18-80 with COVID-19 pneumonia and low oxygen saturation levels. The study seeks to identify clinical indicators that can predict prognosis and treatment responsiveness, particularly in older patients with severe underlying health conditions. By monitoring changes in oxygen levels, the research hopes to provide insights into patient outcomes and treatment efficacy.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-80 with COVID-19 pneumonia and oxygen saturation levels of 93% or lower.
Not a fit: Patients who are pregnant, lactating, or undergoing ECMO, as well as those who refuse monitoring, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the ability to predict outcomes and tailor treatments for COVID-19 patients at risk of respiratory failure.
How similar studies have performed: While there have been studies focusing on oxygen levels in COVID-19 patients, the specific use of PtcO2 as a prognostic tool in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age: 18-80 years, male or female; Patients with COVID-9 pneumonia (typical imaging features of COVID-19 pneumonia) (oxygen saturation ≤ 93% during air or arterial partial pressure of oxygen (PaO2)/oxygen concentration (FiO2) ≤ 300 mmHg at rest)； Exclusion Criteria: * Pregnant or lactating women; Patients who refuse to undergo transcutaneous tissue oxygen pressure monitoring; Clinicians believe that patients are not appropriate; Patients undergoing ECMO.
Where this trial is running
Nanjing, Jiangsu
- Zhongda hospital — Nanjing, Jiangsu, China (Recruiting)
Study contacts
- Principal investigator: Jingyuan Xu, M.D. — Southeast University
- Study coordinator: Jingyuan Xu, M.D.
- Email: 13851417209@163.com
- Phone: 008613851417209
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.